Transcenta procures $100 mln
Transcenta, a China and U.S.-based global biotherapeutics company, has secured $100 million in Series B+ funding.
Transcenta, a China and U.S.-based global biotherapeutics company, has secured $100 million in Series B+ funding.
Copyright PEI Media
Not for publication, email or dissemination